Regenxbio (RGNX) Long-Term Investments (2014 - 2025)
Regenxbio (RGNX) posted quarterly Long-Term Investments of $10.8 million for Q4 2025, up 5.95% year-over-year from $10.2 million in Q4 2024, and down 61.26% quarter-over-quarter from $27.8 million in Q3 2025.
Regenxbio (RGNX) Long-Term Investments (2014 - 2025) Analysis & Trends
Regenxbio's Long-Term Investments history runs 12 years deep, the most recent figure standing at $10.8 million for Q4 2025.
- In Q4 2025, Long-Term Investments rose 5.95% year-over-year to $10.8 million; the TTM figure through Dec 2025 stood at $10.8 million (up 5.95% YoY), while the FY2025 annual figure was $10.8 million, up 5.95% from the prior year.
- Long-Term Investments for Q4 2025 stood at $10.8 million, down from $27.8 million in the prior quarter.
- The five-year high for Long-Term Investments was $391.9 million in Q4 2021, with the low at $4.9 million in Q1 2025.
- The 5-year median for Long-Term Investments is $79.0 million (2023), against an average of $131.9 million.
- The sharpest annual moves came in 2021 and 2025: Long-Term Investments surged 737.25% in 2021, then slumped 88.38% in 2025.
- Regenxbio's Long-Term Investments stood at $391.9 million in 2021, then tumbled by 48.82% to $200.6 million in 2022, then plunged by 80.62% to $38.9 million in 2023, then tumbled by 73.81% to $10.2 million in 2024, then grew by 5.95% to $10.8 million in 2025.
- Business Quant data shows RGNX's Long-Term Investments at $10.8 million in Q4 2025, $27.8 million in Q3 2025, and $40.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.79 Mn |
| Sep 30, 2025 | 27.84 Mn |
| Jun 30, 2025 | 40.30 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | 10.18 Mn |
| Sep 30, 2024 | 23.11 Mn |
| Jun 30, 2024 | 36.94 Mn |
| Mar 31, 2024 | 41.81 Mn |
| Dec 31, 2023 | 38.87 Mn |
| Sep 30, 2023 | 62.64 Mn |
| Jun 30, 2023 | 95.30 Mn |
| Mar 31, 2023 | 141.71 Mn |
| Dec 31, 2022 | 200.56 Mn |
| Sep 30, 2022 | 234.59 Mn |
| Jun 30, 2022 | 279.07 Mn |
| Mar 31, 2022 | 370.66 Mn |
| Dec 31, 2021 | 391.91 Mn |
| Sep 30, 2021 | 193.64 Mn |
| Jun 30, 2021 | 218.22 Mn |
| Mar 31, 2021 | 215.60 Mn |